Latest Insights - page 45 | BiopharmaTrend

Gilead Sciences and Terray Therapeutics Partner to Advance AI-Driven Small Molecule Drug Discovery

Just two months after raising $120 million to advance its AI-driven tNova platform and internal immunology programs, Terray Therapeutics has secured a new research partnership with Gilead Sciences. The collaboration …

Continue ›››

Researchers Discover Role of tRNA Fragments in Cancer Progression

A recent study by researchers at Chung-Ang University, South Korea, published in Nature Communications, reveals how a specific transfer RNA-derived fragment, 5′-tRH-GlyGCC, influences cancer progression. The study highlights this molecule’s …

Continue ›››

Candid and EpimAb Collaborate to Develop T-Cell Engagers for Autoimmune Diseases

After debuting with 370$ million capital raise in September 2024, Candid Therapeutics, a San Diego-based biotechnology company specializing in T-cell engager (TCE) therapies for autoimmune diseases, has announced a research …

Continue ›››

Birmingham Charity Urges Holiday Safety Amid NHS Winter Crisis Talks in the UK

The Royal Society for the Prevention of Accidents (RoSPA) is urging the public to take extra precautions during the festive season as the NHS faces immense pressure amidst a winter …

Continue ›››

BeiGene Enters Global Licensing Agreement for MAT2A Inhibitor SYH2039 to Expand Solid Tumor Pipeline

BeiGene, Ltd. (NASDAQ: BGNE), a global oncology company soon to be renamed BeOne Medicines Ltd., has announced a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel …

Continue ›››

Evaxion Biotech Announces Proof-of-Concept for AI-Driven Cancer Vaccines Targeting Endogenous Retrovirus Tumor Antigens

Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage biotechnology company, has announced preclinical Proof-of-Concept (PoC) results for a precision cancer vaccine concept. The approach uses the company’s AI-Immunology platform to target …

Continue ›››

Elevation Oncology Licenses Synaffix ADC Technology for HER3 ADC Development in a $368 Million Deal

Elevation Oncology has entered into a licensing agreement with Synaffix B.V., a Lonza company, to access its antibody-drug conjugate (ADC) technology. This collaboration enables Elevation Oncology to advance its pipeline …

Continue ›››

Relay Therapeutics Shares Updated Interim Data for Novel PI3Kα Inhibitor in Breast Cancer Treatment

Relay Therapeutics, a clinical-stage precision medicine company, has announced updated interim clinical data for its investigational allosteric PI3Kα inhibitor, RLY-2608, at the San Antonio Breast Cancer Symposium. The data reveal …

Continue ›››

Insilico Medicine Nominates its 21st Pre-Clinical Candidate: An Orally Available NLRP3 Inhibitor for Inflammation and CNS Diseases

Insilico Medicine, a clinical-stage generative AI-driven drug discovery company, has announced the nomination of its 21st pre-clinical candidate, ISM8969, an orally available inhibitor of NLRP3 (NOD-like receptor family pyrin domain …

Continue ›››

Xaira Therapeutics Expands Leadership Team and Moves to New Headquarters

Xaira Therapeutics, an integrated biotechnology company focused on leveraging AI to transform drug discovery and development, announced two key appointments to its leadership team. Dr. Paulo Fontoura will join as …

Continue ›››

Relation Therapeutics Partners with GSK to Develop Treatments for Fibrotic Diseases and Osteoarthritis

Relation Therapeutics announced two strategic collaborations with GSK aimed at advancing drug discovery for fibrotic diseases and osteoarthritis, debilitating conditions with significant unmet medical needs. These collaborations will leverage Relation’s …

Continue ›››

Owkin Shares Federated Learning Tool for Secure RNA-Seq Analysis

Owkin has released FedPyDESeq2, a federated learning tool for differential expression analysis (DEA) in bulk RNA sequencing (RNA-seq). Designed to address challenges in large-scale transcriptomics studies, such as data privacy …

Continue ›››